Highlights GeNeuro SA

Equities

GNRO

CH0308403085

Market Closed - Euronext Paris Other stock markets 16:20:18 10/05/2024 BST			5-day change	1st Jan Change
1.465 ^EUR	-2.33%		-1.68%	+34.40%

03-20	Geneuro SA Announces Appointments of Board of Directors	CI
02-02	GeNeuro: share price falls after private placement	CF

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

GeNeuro: share price falls after private placement	02-02	CF
GeNeuro: Citigroup Global Markets Ltd crosses the 5% threshold	01-05	CF
Geneuro S.A. Recommends Continuing the Trial Evaluating Temelimab in Long Covid Without Modifications	12-11	CI
GeNeuro Announces Completion of Recruitment of its Long-COVID Phase 2 Trial and Confirms Top-Line Results for June 2024	11-28	CI
GeNeuro and Verily Collaborate to Advance Long-COVID Research	19/10/23	CI
GeNeuro SA Reports Earnings Results for the Half Year Ended June 30, 2023	29/09/23	CI
GeNeuro in Collaboration with Heinrich-Heine University Announce Publication in PNAS of Results from their Joint Research on Role of HERV-W in MS	27/09/23	CI
GeNeuro SA Announces Recent Study Demonstrates the Strong Link Between SARS-CoV-2 Infection and HERV-W Activation in Hospitalized Psychotic Patients	11/09/23	CI
GeNeuro SA Reports Earnings Results for the Full Year Ended December 31, 2022	05/04/23	CI
GeNeuro Lands EUR25 Million Loan to Advance Long COVID-19 Trial	07/03/23	MT
GeNeuro SA Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-Covid Assessing Temelimab	16/11/22	CI
Geneuro’S Protect-Ms Phase 2 Trial Data, Presented At the Ectrims 2022 Congress in Amsterdam, Confirms Synergistic Neuroprotective Potential of Temelimab in Ms	28/10/22	CI
GeNeuro Will Present Phase IIb Safety and Efficacy Data on Temelimab from its ProTEct-MS Study at the 38thCongress of the European Committee for Treatment and Research in Multiple Sclerosis	25/10/22	CI
GeNeuro SA Reports Earnings Results for the Half Year Ended June 30, 2022	29/09/22	CI
GeNeuro SA Announces Two Studies on ALS Published in Annals of Neurology Demonstrate the Neurotoxic Role of Human Endogenous Retrovirus Envelope Protein and the Rationale for Targeted Therapy with Specific Antibody	30/08/22	CI
GeNeuro Wins Regulatory Nod To Launch Mid-stage Study Of Post-COVID-19 Drug In Switzerland	12/05/22	MT
Geneuro Is Granted Authorization by the Swiss Health Authority to Initiate A Phase II Study Evaluating Temelimab in Patients with Severe Neuropsychiatric Post-Covid Syndromes	11/05/22	CI
GeNeuro and Fondamental Foundation Announce the First Results of the Collaboration for the Development of Diagnostic and Therapeutic Options for Patients with Post-Covid Neuropsychiatric Syndromes	13/04/22	CI
GeNeuro SA Announces ProTEct-MS Phase 2 Trial Confirms Safety of Higher Doses of Temelimab and Synergistic Potential to Address Neurodegeneration on Top of Anti-inflammatory Treatment in Multiple Sclerosis	21/03/22	CI
GeNeuro Announces the Completion of Its ProTEct-MS Study and Confirms the March Timeline for Top-line Results	27/01/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights GeNeuro SA

Equities

GNRO

CH0308403085

Highlights

Filters